Overview

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Status:
Not yet recruiting

Trial end date:
2024-11-26

Target enrollment:

Participant gender:

Summary

This study aims to establish the recommended dose of [177Lu]Lu-DOTA-TATE in combination with the standard of care or as single agent in three different groups of participants with Glioblastoma. In addition, this study will investigate the safety of [68Ga]Ga-DOTA-TATE and describe its uptake characteristics in participants with Glioblastoma.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Lutetium Lu 177 dotatate
Temozolomide